DNTH
Dianthus Therapeutics, Inc. /DE/
NASDAQ · Healthcare · Biotechnology · US
$106.20
+2.83%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−171.3x
Market Cap
$5.94B
MomentumView details →
1D Return
+2.83%
YTD Return
+160.95%
RSI (14)
49.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−171.3x
Market Cap
$5.94B
RSI (14)
49.8
MomentumView details →
1D Return
+2.83%
YTD Return
+160.95%
SummaryUpdated Jun 1, 2026
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company founded in 2015 and headquartered in New York, New York. The company went public in June 2018 and focuses on developing novel monoclonal antibody treatments for patients suffering from severe autoimmune and inflammatory diseases. Dianthus is currently advancing its lead drug candidate, DNTH103, through Phase 1 clinical trials for multiple neurological conditions including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Similar companies
Latest newsMore news →
Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.40d agoDianthus Therapeutics is advancing DNTH212 for Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis, with Phase 1 healthy volunteer data anticipated by year-end 2026.40d ago